Alogliptin vs Yogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Alogliptin · Nesina

Marketed by Takeda Pharmaceutical Company and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00286429 · Phase 3 · completed

The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.

Next expected readout: December 2026 · NCT07093476 (registry estimate)

Reported efficacy

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)

Result source: NCT02856113

Yogliptin

Developed by Chengdu Easton Biopharmaceuticals

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05318326 · Phase 3 · status unknown

The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlogliptinYogliptin
HbA1c, change-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
—Not reported
Body weight, change (kg)0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
—Not reported
HbA1c below 7%63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
—Not reported
Fasting plasma glucose, change-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
—Not reported
3-point MACE (% with event)11.3% vs 11.8%−0.5 vs placebon 2701NCT00968708—Not reported

HbA1c, change

Alogliptin
-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Yogliptin
—Not reported

Body weight, change (kg)

Alogliptin
0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
Yogliptin
—Not reported

HbA1c below 7%

Alogliptin
63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
Yogliptin
—Not reported

Fasting plasma glucose, change

Alogliptin
-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Yogliptin
—Not reported

3-point MACE (% with event)

Alogliptin
11.3% vs 11.8%−0.5 vs placebon 2701NCT00968708
Yogliptin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Yogliptin: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alogliptin: 4 of 4 rows · Yogliptin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlogliptin
Dropout rate
40.3%25 mg QDa
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
36.6%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.3%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
21.1%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
11%
NCT00968708 · Phase 3
14.9%
NCT01456130 · Phase 3 · registry result, not featured evidence
44.3%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
46.4%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.8%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
6.1%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
36.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
38.8%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
20.5%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
37.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
17.1%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
0%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
4.5%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
21.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
24.2%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
15.4%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.1%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.3%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
11.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
10.8%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
23.2%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
17.1%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
23.2%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
19.6%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
22.3%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
21.4%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
17.4%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
25.3%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
24.6%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1.9%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
5.7%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
2.6%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
6.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
3.8%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
3.8%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
6.3%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
28.9%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
27.3%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
31.1%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
4.7%25 mg QDa
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
0.8%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.3%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
5.6%
NCT00968708 · Phase 3
6%
NCT01456130 · Phase 3 · registry result, not featured evidence
8.4%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
6.8%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
1.1%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
2%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
0%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.2%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
7.4%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
3.6%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
6.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
4.5%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
—25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
—25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.6%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
1.5%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.1%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.8%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.8%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
3.7%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3.7%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
4.1%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
3.3%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
3%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
3.8%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
3.8%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
1.2%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
4.4%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
6.8%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
Serious AEs
5.4%25 mg QDa
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
6.1%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.8%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.7%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
33.6%
NCT00968708 · Phase 3
9%
NCT01456130 · Phase 3 · registry result, not featured evidence
11%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.9%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
2.2%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
0%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
1.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
16.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
16.7%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
0.9%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
3.6%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
1.9%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
8%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
13.6%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
4.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.6%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.3%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.6%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
4.9%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
0.6%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
6.5%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.5%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
3.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2.8%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
5.6%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
5.4%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
2%25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
3.4%25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
10.7%12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
4.9%12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
2.9%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
1.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
8.2%25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
7.9%12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
5.2%50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
2.1%6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.4%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
2.4%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
10%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
25 mg QDa
urinary tract infection 7% (placebo 7.8%)
diarrhoea 6.2% (placebo 5.4%)
nasopharyngitis 6.2% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
12.5 mg QD
arthralgia 6.9% (placebo 2.3%)
urinary tract infection 6.1% (placebo 7.8%)
headache 5.3% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
25 mg QD
nasopharyngitis 7.6% (placebo 7.8%)
headache 6.8% (placebo 4.7%)
upper respiratory tract infection 4.5% (placebo 9.4%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
12.5 mg QD
nasopharyngitis 9% (placebo 7.8%)
headache 7.5% (placebo 4.7%)
back pain 5.3% (placebo 4.7%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
25 mg
headache 18.7% (placebo 10.5%)
hyperglycaemia 12% (placebo 11.8%)
diarrhoea 9.3% (placebo 9.2%)
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
renal impairment 7.5% (placebo 6.5%)
hypertension 7.1% (placebo 7.4%)
hypoglycaemia 6.2% (placebo 5.9%)
NCT00968708 · Phase 3
nasopharyngitis 35.8%
upper respiratory tract inflammation 11.9%
arthralgia 7.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
25 mg
upper respiratory tract infection 10.3%
hypertension 7.6%
nasopharyngitis 7.6%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
12.5 mg
upper respiratory tract infection 9.6%
nasopharyngitis 8.9%
diarrhoea 6.9%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 6.5% (placebo 1.1%)
upper respiratory tract infection 5.4% (placebo 3.3%)
blood triglycerides increased 2.2% (placebo 1.1%)
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
upper respiratory tract infection 3% (placebo 3.3%)
blood triglycerides increased 2% (placebo 1.1%)
urinary tract infection 2% (placebo 6.5%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 21.3% (placebo 1.1%)
urinary tract infection 6.6% (placebo 6.5%)
upper respiratory tract infection 3.3% (placebo 3.3%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
25 mg
hypertension 14.5%
urinary tract infection 11.7%
nasopharyngitis 11.6%
NCT00306384 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertension 14.8%
upper respiratory tract infection 11.6%
urinary tract infection 11.1%
NCT00306384 · Phase 3 · registry result, not featured evidence
25 mg QD
hyperglycaemia 17% (placebo 26.4%)
nasopharyngitis 6.3% (placebo 1.9%)
headache 5.4% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
12.5 mg BID
hyperglycaemia 11.8% (placebo 26.4%)
headache 4.5% (placebo 2.8%)
creatinine renal clearance decreased 3.6% (placebo 3.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
alogliptin 12.5 mg BID + metformin 1000 mg BID
creatinine renal clearance decreased 7.9% (placebo 3.8%)
diarrhoea 7% (placebo 2.8%)
dyspepsia 7% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
alogliptin 12.5 mg BID + metformin 500 mg BID
hyperglycaemia 7.5% (placebo 26.4%)
upper respiratory tract infection 7.5% (placebo 2.8%)
headache 6.6% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 20% (placebo 4.2%)
anaemia 12% (placebo 4.2%)
constipation 8% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence
25 mg QD + 30 mg QD
hypoglycaemia 13.6% (placebo 0%)
nasopharyngitis 13.6% (placebo 4.2%)
constipation 9.1% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
upper respiratory tract infection 7.2%
nasopharyngitis 6.9%
hypertension 5.9%
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 7% (placebo 4.7%)
upper respiratory tract infection 6.2% (placebo 3.9%)
abdominal pain upper 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertriglyceridaemia 5.5% (placebo 2.3%)
hypertension 4.7% (placebo 3.1%)
urinary tract infection 4.7% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence
25 mg + 15 mg
influenza 6.2% (placebo 2.3%)
nasopharyngitis 6.2% (placebo 3.9%)
oedema peripheral 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 30 mg
nasopharyngitis 6.9% (placebo 3.9%)
back pain 6.2% (placebo 3.9%)
influenza 6.2% (placebo 2.3%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 45 mg
diarrhoea 5.4% (placebo 8.5%)
headache 4.6% (placebo 4.7%)
oedema peripheral 4.6% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 15 mg
hypertension 6.9% (placebo 3.1%)
nasopharyngitis 6.2% (placebo 3.9%)
dizziness 5.4% (placebo 3.1%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
dizziness 3.8% (placebo 3.1%)
nasopharyngitis 3.8% (placebo 3.9%)
upper respiratory tract infection 3.8% (placebo 3.9%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 45 mg
back pain 9.2% (placebo 3.9%)
dizziness 4.6% (placebo 3.1%)
headache 4.6% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 6.7%
urinary tract infection 3%
oedema peripheral 1.2%
NCT00395512 · Phase 3 · registry result, not featured evidence
25 mg + 30 mg
headache 12.2%
back pain 6.1%
urinary tract infection 5.5%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
headache 8.6%
urinary tract infection 3.7%
back pain 1.8%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 7% (placebo 6.2%)
influenza 5.5% (placebo 4.1%)
oedema peripheral 5.5% (placebo 7.2%)
NCT00286494 · Phase 3 · registry result, not featured evidence
12.5 mg QD
oedema peripheral 6.1% (placebo 7.2%)
upper respiratory tract infection 5.6% (placebo 5.2%)
nausea 4.5% (placebo 2.1%)
NCT00286494 · Phase 3 · registry result, not featured evidence
25 mg QD
diarrhoea 3.4% (placebo 5.8%)
nasopharyngitis 3.4% (placebo 5.8%)
bronchitis 2.9% (placebo 1.9%)
NCT00286442 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 6.6% (placebo 3.8%)
nasopharyngitis 5.6% (placebo 5.8%)
upper respiratory tract infection 4.7% (placebo 6.7%)
NCT00286442 · Phase 3 · registry result, not featured evidence
25 mg QD
headache 5.6% (placebo 3%)
hypertension 5.6% (placebo 2%)
urinary tract infection 5.1% (placebo 3%)
NCT00286468 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 4.4% (placebo 3%)
diarrhoea 3.9% (placebo 0%)
hypertriglyceridaemia 3.9% (placebo 2%)
NCT00286468 · Phase 3 · registry result, not featured evidence
25 mg QD and 1-6 mg QD or BID
nasopharyngitis 37.5%
upper respiratory tract inflammation 10.5%
fall 7.9%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 36.6%
diabetic retinopathy 6.9%
constipation 5.5%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 1-6 mg QD or BID
nasopharyngitis 30.7%
upper respiratory tract inflammation 6.7%
back pain 5.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 31%
back pain 6.3%
headache 6.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 19.2%
upper respiratory tract inflammation 11.5%
back pain 3.8%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 19%
gastroenteritis 3.8%
upper respiratory tract inflammation 1.9%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 25 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 28.6%
back pain 5.7%
arthralgia 4.8%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 35.2%
upper respiratory tract inflammation 11.1%
back pain 7.4%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 11.5%
blood creatine phosphokinase increased 3.5%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 4.5%
blood creatine phosphokinase increased 0%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 22.4%
eczema 1.3%
NCT01263483 · Phase 2/3 · registry result, not featured evidence
25 mg QD + 0.2 mg TID
nasopharyngitis 16.5%
eczema 0%
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 33%
headache 7.2%
upper respiratory tract inflammation 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 28.7%
bronchitis 5.9%
back pain 5%
NCT01263496 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 35.1%
blood creatine phosphokinase increased 8.2%
back pain 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 30.2%
upper respiratory tract inflammation 8.3%
back pain 7.3%
NCT01263496 · Phase 2 · registry result, not featured evidence
25 mg QD
nasopharyngitis 12.5% (placebo 6.7%)
headache 6.3% (placebo 5.3%)
abdominal distension 3.8% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 8.3% (placebo 6.7%)
flatulence 4.8% (placebo 2.7%)
urticaria 3.6% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 10.1% (placebo 6.7%)
blood creatine phosphokinase increased 5.1% (placebo 2.7%)
abdominal distension 2.5% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 6.3% (placebo 6.7%)
bronchitis 3.8% (placebo 1.3%)
flatulence 2.5% (placebo 2.7%)
NCT01263470 · Phase 2 · registry result, not featured evidence
25 mg QD
headache 8.9% (placebo 7.3%)
abdominal pain upper 6.7% (placebo 0%)
dizziness 6.7% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
12.5 mg QD
rash 9.1% (placebo 2.4%)
abdominal pain 4.5% (placebo 0%)
arthralgia 4.5% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
100 mg QD
nausea 11.4% (placebo 0%)
headache 9.1% (placebo 7.3%)
urinary tract infection 9.1% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
50 mg QD
diarrhoea 7% (placebo 7.3%)
headache 7% (placebo 7.3%)
urinary tract infection 7% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
6.25 mg QD
urinary tract infection 7.1% (placebo 9.8%)
abdominal pain upper 4.8% (placebo 0%)
dizziness 4.8% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
25 mg
rash papular 25%
abdominal pain 0%
blood creatine phosphokinase increased 0%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
blood creatine phosphokinase increased 14.3%
haematocrit decreased 14.3%
haemoglobin decreased 14.3%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
headache 18.2%
fatigue 9.1%
nausea 9.1%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
diarrhoea 20%
neutrophil count decreased 20%
pyrexia 20%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
abdominal pain 25%
gastritis 12.5%
headache 12.5%
NCT00957268 · Phase 1 · registry result, not featured evidence
headache 30%
nausea 20%
constipation 10%
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
nausea 50%
diarrhoea 40%
vomiting 30%
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 65 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alogliptin

HbA1c -0.71% (n=126) vs -0.13% (n=126) placebo @ 26wk25 mg QD
absolute change · percentage points
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 285 more results
-0.58% (n=116) vs -0.26% (n=114) placebo @ 4wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=126) vs -0.27% (n=126) placebo @ 8wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.81% (n=126) vs -0.27% (n=126) placebo @ 12wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.76% (n=126) vs -0.22% (n=126) placebo @ 16wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.74% (n=126) vs -0.17% (n=126) placebo @ 20wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.59% (n=128) vs -0.02% (n=63) placebo @ 26wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.45% (n=120) vs -0.11% (n=59) placebo @ 4wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.64% (n=128) vs -0.13% (n=63) placebo @ 8wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.66% (n=128) vs -0.13% (n=63) placebo @ 12wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.65% (n=128) vs -0.12% (n=63) placebo @ 16wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.61% (n=128) vs -0.12% (n=63) placebo @ 20wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.091% (n=54) vs -0.011% (n=56) placebo @ 26wk25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
-0.365% (n=62) vs -0.319% (n=62) placebo @ 12wk25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
-0.202% (n=62) vs -0.206% (n=62) placebo @ 18wk25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
0.091% (n=62) vs 0.502% (n=62) placebo @ 39wk25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
0.281% (n=62) vs 0.764% (n=62) placebo @ 52wk25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
-0.52% (n=104) vs 0.15% (n=102) placebo @ 26wk25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.34% (n=112) vs 0.09% (n=106) placebo @ 4wk25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.51% (n=112) vs 0.08% (n=106) placebo @ 8wk25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.53% (n=112) vs 0.12% (n=106) placebo @ 12wk25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.58% (n=112) vs 0.13% (n=106) placebo @ 16wk25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.57% (n=112) vs 0.12% (n=106) placebo @ 20wk25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.51% (n=110) vs -0.22% (n=120) placebo @ 4wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.8% (n=123) vs -0.3% (n=126) placebo @ 8wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.92% (n=123) vs -0.28% (n=126) placebo @ 12wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-1.03% (n=123) vs -0.27% (n=126) placebo @ 16wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.99% (n=123) vs -0.24% (n=126) placebo @ 20wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.9% (n=123) vs -0.13% (n=126) placebo @ 26wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.96% (n=160) vs -1.15% (n=153) Pioglitazone 30 mg @ 26wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.55% (n=164) vs -0.3% (n=163) Pioglitazone 30 mg @ 4wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.84% (n=164) vs -0.72% (n=163) Pioglitazone 30 mg @ 8wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.98% (n=164) vs -1.04% (n=163) Pioglitazone 30 mg @ 12wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-1.01% (n=164) vs -1.17% (n=163) Pioglitazone 30 mg @ 16wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-1% (n=164) vs -1.2% (n=163) Pioglitazone 30 mg @ 20wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.8% (n=195) vs -0.19% (n=95) placebo @ 26wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.45% (n=176) vs -0.14% (n=90) placebo @ 4wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.73% (n=195) vs -0.18% (n=95) placebo @ 8wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.82% (n=195) vs -0.23% (n=95) placebo @ 12wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.84% (n=195) vs -0.26% (n=95) placebo @ 16wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.82% (n=195) vs -0.27% (n=95) placebo @ 20wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.59% (n=203) vs -0.1% (n=103) placebo @ 26wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.4% (n=187) vs -0.1% (n=91) placebo @ 4wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.59% (n=201) vs -0.21% (n=103) placebo @ 8wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.66% (n=203) vs -0.16% (n=103) placebo @ 12wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.64% (n=203) vs -0.13% (n=103) placebo @ 16wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.63% (n=203) vs -0.12% (n=103) placebo @ 20wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.74% (n=94) vs -0.15% (n=79) Voglibose @ 12wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.77% (n=89) vs -0.25% (n=71) Voglibose @ 16wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.7% (n=88) vs -0.3% (n=69) Voglibose @ 20wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.66% (n=89) vs -0.29% (n=66) Voglibose @ 24wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.67% (n=87) vs -0.32% (n=65) Voglibose @ 28wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.61% (n=87) vs -0.27% (n=64) Voglibose @ 32wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.66% (n=82) vs -0.28% (n=64) Voglibose @ 36wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.66% (n=79) vs -0.28% (n=63) Voglibose @ 40wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.71% (n=63) vs -0.35% (n=63) Voglibose @ 44wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.76% (n=62) vs -0.4% (n=61) Voglibose @ 48wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.74% (n=62) vs -0.37% (n=61) Voglibose @ 52wk25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.63% (n=96) vs -0.22% (n=83) Voglibose25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.76% (n=79) vs 0.06% (n=75) placebo @ 12wk25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.16% (n=79) vs 0% (n=75) placebo @ 2wk25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.35% (n=79) vs -0.01% (n=75) placebo @ 4wk25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.66% (n=79) vs 0% (n=75) placebo @ 8wk25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.56% (n=45) vs -0.01% (n=41) placebo @ 12.14wk25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.36% (n=44) vs 0.02% (n=41) placebo @ 6.14wk25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.63% (n=130) vs -0.13% (n=126) placebo @ 26wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.47% (n=116) vs -0.26% (n=114) placebo @ 4wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.76% (n=130) vs -0.27% (n=126) placebo @ 8wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=130) vs -0.27% (n=126) placebo @ 12wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.8% (n=130) vs -0.22% (n=126) placebo @ 16wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.76% (n=130) vs -0.17% (n=126) placebo @ 20wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.56% (n=131) vs -0.02% (n=63) placebo @ 26wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.37% (n=123) vs -0.11% (n=59) placebo @ 4wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.53% (n=131) vs -0.13% (n=63) placebo @ 8wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.57% (n=131) vs -0.13% (n=63) placebo @ 12wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.59% (n=131) vs -0.12% (n=63) placebo @ 16wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.58% (n=131) vs -0.12% (n=63) placebo @ 20wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.56% (n=104) vs 0.15% (n=102) placebo @ 26wk12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.42% (n=110) vs 0.09% (n=106) placebo @ 4wk12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.58% (n=110) vs 0.08% (n=106) placebo @ 8wk12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.62% (n=110) vs 0.12% (n=106) placebo @ 12wk12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.63% (n=110) vs 0.13% (n=106) placebo @ 16wk12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.59% (n=110) vs 0.12% (n=106) placebo @ 20wk12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
-0.46% (n=114) vs -0.22% (n=120) placebo @ 4wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.75% (n=122) vs -0.3% (n=126) placebo @ 8wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.84% (n=122) vs -0.28% (n=126) placebo @ 12wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.82% (n=122) vs -0.27% (n=126) placebo @ 16wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.75% (n=122) vs -0.24% (n=126) placebo @ 20wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.64% (n=122) vs -0.13% (n=126) placebo @ 26wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.66% (n=196) vs -0.19% (n=95) placebo @ 26wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.4% (n=182) vs -0.14% (n=90) placebo @ 4wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.6% (n=196) vs -0.18% (n=95) placebo @ 8wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.7% (n=196) vs -0.23% (n=95) placebo @ 12wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.7% (n=196) vs -0.26% (n=95) placebo @ 16wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.68% (n=196) vs -0.27% (n=95) placebo @ 20wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.61% (n=210) vs -0.1% (n=103) placebo @ 26wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.36% (n=188) vs -0.1% (n=91) placebo @ 4wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.59% (n=210) vs -0.21% (n=103) placebo @ 8wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.66% (n=210) vs -0.16% (n=103) placebo @ 12wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.66% (n=210) vs -0.13% (n=103) placebo @ 16wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.63% (n=210) vs -0.12% (n=103) placebo @ 20wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.96% (n=76) vs 0.04% (n=74) Voglibose @ 12wk12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.19% (n=76) vs -0.01% (n=74) Voglibose @ 2wk12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.44% (n=76) vs -0.02% (n=74) Voglibose @ 4wk12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.74% (n=76) vs -0.01% (n=74) Voglibose @ 8wk12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.7% (n=97) vs -0.15% (n=79) Voglibose @ 12wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.75% (n=89) vs -0.25% (n=71) Voglibose @ 16wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.69% (n=87) vs -0.3% (n=69) Voglibose @ 20wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.61% (n=84) vs -0.29% (n=66) Voglibose @ 24wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.56% (n=82) vs -0.32% (n=65) Voglibose @ 28wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.56% (n=81) vs -0.27% (n=64) Voglibose @ 32wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.52% (n=81) vs -0.28% (n=64) Voglibose @ 36wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.48% (n=79) vs -0.28% (n=63) Voglibose @ 40wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.59% (n=61) vs -0.35% (n=63) Voglibose @ 44wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.66% (n=60) vs -0.4% (n=61) Voglibose @ 48wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.65% (n=59) vs -0.37% (n=61) Voglibose @ 52wk12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.47% (n=101) vs -0.22% (n=83) Voglibose12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.7% (n=84) vs 0.06% (n=75) placebo @ 12wk12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.17% (n=84) vs 0% (n=75) placebo @ 2wk12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.38% (n=84) vs -0.01% (n=75) placebo @ 4wk12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.61% (n=84) vs 0% (n=75) placebo @ 8wk12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.54% (n=42) vs -0.01% (n=41) placebo @ 12.14wk12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.35% (n=42) vs 0.02% (n=41) placebo @ 6.14wk12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.51% (n=44) vs -0.01% (n=41) placebo @ 12.14wk100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.31% (n=44) vs 0.02% (n=41) placebo @ 6.14wk100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.86% (n=94) vs -0.15% (n=79) Voglibose @ 12wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.9% (n=91) vs -0.25% (n=71) Voglibose @ 16wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.88% (n=90) vs -0.3% (n=69) Voglibose @ 20wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.83% (n=89) vs -0.29% (n=66) Voglibose @ 24wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.78% (n=86) vs -0.32% (n=65) Voglibose @ 28wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.76% (n=85) vs -0.27% (n=64) Voglibose @ 32wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.77% (n=84) vs -0.28% (n=64) Voglibose @ 36wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.77% (n=84) vs -0.28% (n=63) Voglibose @ 40wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.79% (n=69) vs -0.35% (n=63) Voglibose @ 44wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.83% (n=69) vs -0.4% (n=61) Voglibose @ 48wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.85% (n=68) vs -0.37% (n=61) Voglibose @ 52wk50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.86% (n=97) vs -0.22% (n=83) Voglibose50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.82% (n=79) vs 0.06% (n=75) placebo @ 12wk50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.15% (n=79) vs 0% (n=75) placebo @ 2wk50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.4% (n=79) vs -0.01% (n=75) placebo @ 4wk50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.69% (n=79) vs 0% (n=75) placebo @ 8wk50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.44% (n=43) vs -0.01% (n=41) placebo @ 12.14wk50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.32% (n=43) vs 0.02% (n=41) placebo @ 6.14wk50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.76% (n=382) vs -0.73% (n=336) Glipizide @ 52wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.4% (n=382) vs -0.41% (n=336) Glipizide @ 4wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.6% (n=382) vs -0.66% (n=336) Glipizide @ 8wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.71% (n=382) vs -0.78% (n=336) Glipizide @ 12wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.76% (n=382) vs -0.78% (n=336) Glipizide @ 16wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.78% (n=382) vs -0.79% (n=336) Glipizide @ 20wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.79% (n=382) vs -0.8% (n=336) Glipizide @ 26wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.81% (n=382) vs -0.74% (n=336) Glipizide @ 39wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.83% (n=382) vs -0.76% (n=336) Glipizide @ 65wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.8% (n=382) vs -0.73% (n=336) Glipizide @ 78wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.77% (n=382) vs -0.68% (n=336) Glipizide @ 91wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.72% (n=382) vs -0.59% (n=336) Glipizide @ 104wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.89% (n=303) vs -0.42% (n=306) Pioglitazone 45 mg + Metformin @ 26wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.7% (n=303) vs -0.29% (n=306) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.42% (n=303) vs -0.15% (n=306) Pioglitazone 45 mg + Metformin @ 4wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.71% (n=303) vs -0.27% (n=306) Pioglitazone 45 mg + Metformin @ 8wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.85% (n=303) vs -0.35% (n=306) Pioglitazone 45 mg + Metformin @ 12wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.91% (n=303) vs -0.43% (n=306) Pioglitazone 45 mg + Metformin @ 16wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.91% (n=303) vs -0.45% (n=306) Pioglitazone 45 mg + Metformin @ 20wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.82% (n=303) vs -0.37% (n=306) Pioglitazone 45 mg + Metformin @ 34wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.8% (n=303) vs -0.36% (n=306) Pioglitazone 45 mg + Metformin @ 42wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.61% (n=116) vs -0.22% (n=120) placebo @ 4wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-0.6% (n=118) vs -0.22% (n=120) placebo @ 4wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-0.63% (n=112) vs -0.22% (n=120) placebo @ 4wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.04% (n=127) vs -0.3% (n=126) placebo @ 8wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.02% (n=124) vs -0.3% (n=126) placebo @ 8wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.2% (n=126) vs -0.3% (n=126) placebo @ 8wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.26% (n=127) vs -0.28% (n=126) placebo @ 12wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.33% (n=124) vs -0.28% (n=126) placebo @ 12wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.53% (n=126) vs -0.28% (n=126) placebo @ 12wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.36% (n=127) vs -0.27% (n=126) placebo @ 16wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.45% (n=124) vs -0.27% (n=126) placebo @ 16wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.66% (n=126) vs -0.27% (n=126) placebo @ 16wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.37% (n=127) vs -0.24% (n=126) placebo @ 20wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.49% (n=124) vs -0.24% (n=126) placebo @ 20wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.66% (n=126) vs -0.24% (n=126) placebo @ 20wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.27% (n=127) vs -0.13% (n=126) placebo @ 26wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.39% (n=124) vs -0.13% (n=126) placebo @ 26wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.6% (n=126) vs -0.13% (n=126) placebo @ 26wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.71% (n=158) vs -1.15% (n=153) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-0.62% (n=164) vs -0.3% (n=163) Pioglitazone 30 mg @ 4wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.19% (n=164) vs -0.72% (n=163) Pioglitazone 30 mg @ 8wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.57% (n=164) vs -1.04% (n=163) Pioglitazone 30 mg @ 12wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.67% (n=164) vs -1.17% (n=163) Pioglitazone 30 mg @ 16wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.72% (n=164) vs -1.2% (n=163) Pioglitazone 30 mg @ 20wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-0.66% (n=104) vs 0.34% (n=103) Glimepiride @ 12wk25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.13% (n=104) vs 0.08% (n=103) Glimepiride @ 2wk25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.36% (n=104) vs 0.09% (n=103) Glimepiride @ 4wk25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.59% (n=104) vs 0.18% (n=103) Glimepiride @ 8wk25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.22% (n=111) vs -0.04% (n=115) Pioglitazone @ 2wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.46% (n=113) vs -0.1% (n=115) Pioglitazone @ 4wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=113) vs -0.17% (n=115) Pioglitazone @ 8wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.97% (n=113) vs -0.19% (n=115) Pioglitazone @ 12wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.91% (n=79) vs 0.04% (n=74) Voglibose @ 12wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.21% (n=79) vs -0.01% (n=74) Voglibose @ 2wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.43% (n=79) vs -0.02% (n=74) Voglibose @ 4wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.75% (n=79) vs -0.01% (n=74) Voglibose @ 8wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=371) vs -0.73% (n=336) Glipizide @ 52wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.37% (n=371) vs -0.41% (n=336) Glipizide @ 4wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.56% (n=371) vs -0.66% (n=336) Glipizide @ 8wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.69% (n=371) vs -0.78% (n=336) Glipizide @ 12wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.74% (n=371) vs -0.78% (n=336) Glipizide @ 16wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.76% (n=371) vs -0.79% (n=336) Glipizide @ 20wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.8% (n=371) vs -0.8% (n=336) Glipizide @ 26wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.81% (n=371) vs -0.74% (n=336) Glipizide @ 39wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.81% (n=371) vs -0.76% (n=336) Glipizide @ 65wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.82% (n=371) vs -0.73% (n=336) Glipizide @ 78wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.76% (n=371) vs -0.68% (n=336) Glipizide @ 91wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.68% (n=371) vs -0.59% (n=336) Glipizide @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-1.22% (n=102) vs 0.15% (n=102) placebo @ 26wkalogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.55% (n=111) vs 0.15% (n=102) placebo @ 26wkalogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-0.7% (n=106) vs 0.09% (n=106) placebo @ 4wkalogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-0.75% (n=114) vs 0.09% (n=106) placebo @ 4wkalogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.08% (n=106) vs 0.08% (n=106) placebo @ 8wkalogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.17% (n=114) vs 0.08% (n=106) placebo @ 8wkalogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.22% (n=106) vs 0.12% (n=106) placebo @ 12wkalogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.4% (n=114) vs 0.12% (n=106) placebo @ 12wkalogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.26% (n=106) vs 0.13% (n=106) placebo @ 16wkalogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.5% (n=114) vs 0.13% (n=106) placebo @ 16wkalogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.25% (n=106) vs 0.12% (n=106) placebo @ 20wkalogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-1.54% (n=114) vs 0.12% (n=106) placebo @ 20wkalogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
-0.53% (n=120) vs -0.22% (n=120) placebo @ 4wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-0.6% (n=122) vs -0.22% (n=120) placebo @ 4wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-0.58% (n=117) vs -0.22% (n=120) placebo @ 4wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.01% (n=130) vs -0.3% (n=126) placebo @ 8wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.05% (n=128) vs -0.3% (n=126) placebo @ 8wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.11% (n=127) vs -0.3% (n=126) placebo @ 8wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.24% (n=130) vs -0.28% (n=126) placebo @ 12wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.29% (n=128) vs -0.28% (n=126) placebo @ 12wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.34% (n=127) vs -0.28% (n=126) placebo @ 12wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.36% (n=130) vs -0.27% (n=126) placebo @ 16wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.42% (n=128) vs -0.27% (n=126) placebo @ 16wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.53% (n=127) vs -0.27% (n=126) placebo @ 16wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.39% (n=130) vs -0.24% (n=126) placebo @ 20wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.43% (n=128) vs -0.24% (n=126) placebo @ 20wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.57% (n=127) vs -0.24% (n=126) placebo @ 20wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.34% (n=130) vs -0.13% (n=126) placebo @ 26wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.39% (n=128) vs -0.13% (n=126) placebo @ 26wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.55% (n=127) vs -0.13% (n=126) placebo @ 26wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
-1.56% (n=158) vs -1.15% (n=153) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-0.51% (n=163) vs -0.3% (n=163) Pioglitazone 30 mg @ 4wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.03% (n=163) vs -0.72% (n=163) Pioglitazone 30 mg @ 8wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.34% (n=163) vs -1.04% (n=163) Pioglitazone 30 mg @ 12wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.43% (n=163) vs -1.17% (n=163) Pioglitazone 30 mg @ 16wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-1.54% (n=163) vs -1.2% (n=163) Pioglitazone 30 mg @ 20wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-0.6% (n=104) vs 0.34% (n=103) Glimepiride @ 12wk12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.12% (n=104) vs 0.08% (n=103) Glimepiride @ 2wk12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.32% (n=104) vs 0.09% (n=103) Glimepiride @ 4wk12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.52% (n=104) vs 0.18% (n=103) Glimepiride @ 8wk12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
-0.22% (n=110) vs -0.04% (n=115) Pioglitazone @ 2wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.47% (n=111) vs -0.1% (n=115) Pioglitazone @ 4wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.76% (n=111) vs -0.17% (n=115) Pioglitazone @ 8wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.91% (n=111) vs -0.19% (n=115) Pioglitazone @ 12wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.55% (n=93) vs -0.15% (n=79) Voglibose @ 12wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.57% (n=88) vs -0.25% (n=71) Voglibose @ 16wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.56% (n=87) vs -0.3% (n=69) Voglibose @ 20wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.47% (n=86) vs -0.29% (n=66) Voglibose @ 24wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.39% (n=85) vs -0.32% (n=65) Voglibose @ 28wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.35% (n=84) vs -0.27% (n=64) Voglibose @ 32wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.33% (n=82) vs -0.28% (n=64) Voglibose @ 36wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.33% (n=81) vs -0.28% (n=63) Voglibose @ 40wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.29% (n=65) vs -0.35% (n=63) Voglibose @ 44wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.43% (n=63) vs -0.4% (n=61) Voglibose @ 48wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.49% (n=62) vs -0.37% (n=61) Voglibose @ 52wk6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.4% (n=96) vs -0.22% (n=83) Voglibose6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
-0.51% (n=79) vs 0.06% (n=75) placebo @ 12wk6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.16% (n=79) vs 0% (n=75) placebo @ 2wk6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.34% (n=79) vs -0.01% (n=75) placebo @ 4wk6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.5% (n=79) vs 0% (n=75) placebo @ 8wk6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
-0.19% (n=42) vs -0.01% (n=41) placebo @ 12.14wk6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.12% (n=42) vs 0.02% (n=41) placebo @ 6.14wk6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
-0.99% (n=90) vs -0.42% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.91% (n=98) vs -0.42% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.76% (n=60) vs -0.42% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.56% (n=92) vs -0.24% (n=92) placebo @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.43% (n=99) vs -0.24% (n=92) placebo @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.44% (n=61) vs -0.24% (n=92) placebo @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=92) vs -0.39% (n=92) placebo @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.66% (n=99) vs -0.39% (n=92) placebo @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.7% (n=61) vs -0.39% (n=92) placebo @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.99% (n=92) vs -0.41% (n=92) placebo @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.86% (n=99) vs -0.41% (n=92) placebo @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.77% (n=61) vs -0.41% (n=92) placebo @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -0.55 vs 0.35 placebo mmol/L @ 1wk25 mg QD
absolute change · mmol/L
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.9 mg/dL as posted
show 351 more results
-0.63 vs 0.06 placebo mmol/L @ 2wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -11.4 mg/dL as posted
-0.67 vs 0.29 placebo mmol/L @ 4wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.1 mg/dL as posted
-0.78 vs 0.3 placebo mmol/L @ 8wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.1 mg/dL as posted
-0.16 vs -0.08 placebo mmol/L @ 12wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -2.9 mg/dL as posted
-0.35 vs 0.26 placebo mmol/L @ 16wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -6.3 mg/dL as posted
-0.63 vs 0.48 placebo mmol/L @ 20wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -11.3 mg/dL as posted
-0.65 vs 0.32 placebo mmol/L @ 26wk*25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -11.7 mg/dL as posted
-0.78 vs 0.26 placebo mmol/L @ 1wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -14 mg/dL as posted
-0.98 vs 0.21 placebo mmol/L @ 2wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -17.6 mg/dL as posted
-1.2 vs 0.16 placebo mmol/L @ 4wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -21.6 mg/dL as posted
-1.1 vs 0.14 placebo mmol/L @ 8wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -19.8 mg/dL as posted
-1.11 vs 0.07 placebo mmol/L @ 12wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -20 mg/dL as posted
-1.01 vs 0.29 placebo mmol/L @ 16wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -18.2 mg/dL as posted
-0.96 vs 0.39 placebo mmol/L @ 20wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -17.3 mg/dL as posted
-0.91 vs 0.63 placebo mmol/L @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.4 mg/dL as posted
-0.22 vs 0.32 placebo mmol/L @ 1wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -3.9 mg/dL as posted
-0.41 vs 0.26 placebo mmol/L @ 2wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.4 mg/dL as posted
-0.64 vs 0.4 placebo mmol/L @ 4wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.5 mg/dL as posted
-0.61 vs 0.39 placebo mmol/L @ 8wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.9 mg/dL as posted
-0.54 vs 0.64 placebo mmol/L @ 12wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -9.7 mg/dL as posted
-0.39 vs 0.56 placebo mmol/L @ 16wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.1 mg/dL as posted
-0.51 vs 0.48 placebo mmol/L @ 20wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -9.2 mg/dL as posted
-0.34 vs 0.69 placebo mmol/L @ 26wk*25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -6.1 mg/dL as posted
-1.15 vs -0.23 placebo mmol/L @ 4wk*25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.669 mg/dL as posted
-0.9 vs 0.27 placebo mmol/L @ 8wk*25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.293 mg/dL as posted
-0.95 vs 0.66 placebo mmol/L @ 16wk*25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.052 mg/dL as posted
-1.03 vs 0.1 placebo mmol/L @ 1wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.6 mg/dL as posted
-1.05 vs 0.27 placebo mmol/L @ 2wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.9 mg/dL as posted
-1.27 vs 0.21 placebo mmol/L @ 4wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.8 mg/dL as posted
-1.07 vs 0.32 placebo mmol/L @ 8wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.3 mg/dL as posted
-1.29 vs 0.19 placebo mmol/L @ 12wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -23.3 mg/dL as posted
-1.25 vs 0.08 placebo mmol/L @ 16wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.6 mg/dL as posted
-1.3 vs 0.37 placebo mmol/L @ 20wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -23.5 mg/dL as posted
-1.03 vs 0.36 placebo mmol/L @ 26wk*25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.6 mg/dL as posted
-0.81 vs -0.41 Pioglitazone 30 mg mmol/L @ 1wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.6 mg/dL as posted
-0.93 vs -0.79 Pioglitazone 30 mg mmol/L @ 2wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.7 mg/dL as posted
-1.48 vs -1.77 Pioglitazone 30 mg mmol/L @ 4wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.7 mg/dL as posted
-1.61 vs -2.11 Pioglitazone 30 mg mmol/L @ 8wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -29 mg/dL as posted
-1.64 vs -2.35 Pioglitazone 30 mg mmol/L @ 12wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -29.5 mg/dL as posted
-1.49 vs -2.25 Pioglitazone 30 mg mmol/L @ 16wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.9 mg/dL as posted
-1.57 vs -2.33 Pioglitazone 30 mg mmol/L @ 20wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -28.3 mg/dL as posted
-1.43 vs -2.07 Pioglitazone 30 mg mmol/L @ 26wk*25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -25.8 mg/dL as posted
-1.01 vs -0.15 placebo mmol/L @ 1wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.2 mg/dL as posted
-1.18 vs -0.1 placebo mmol/L @ 2wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.2 mg/dL as posted
-1.44 vs -0.17 placebo mmol/L @ 4wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26 mg/dL as posted
-1.5 vs -0.34 placebo mmol/L @ 8wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -27.1 mg/dL as posted
-1.45 vs -0.55 placebo mmol/L @ 12wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.2 mg/dL as posted
-1.27 vs -0.46 placebo mmol/L @ 16wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.8 mg/dL as posted
-1.2 vs -0.36 placebo mmol/L @ 20wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.6 mg/dL as posted
-1.1 vs -0.32 placebo mmol/L @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.9 mg/dL as posted
-0.69 vs -0.03 placebo mmol/L @ 1wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12.5 mg/dL as posted
-0.98 vs -0.04 placebo mmol/L @ 2wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.6 mg/dL as posted
-1 vs -0.03 placebo mmol/L @ 4wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.1 mg/dL as posted
-0.95 vs 0.02 placebo mmol/L @ 8wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.2 mg/dL as posted
-0.93 vs 0.02 placebo mmol/L @ 12wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.8 mg/dL as posted
-0.85 vs 0.07 placebo mmol/L @ 16wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -15.4 mg/dL as posted
-0.87 vs -0.01 placebo mmol/L @ 20wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -15.6 mg/dL as posted
-0.97 vs 0 placebo mmol/L @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.4 mg/dL as posted
-1.05 vs 0.02 placebo mmol/L @ 1wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19 mg/dL as posted
-1.21 vs -0.1 placebo mmol/L @ 2wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.8 mg/dL as posted
-1.17 vs -0.21 placebo mmol/L @ 4wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.1 mg/dL as posted
-1.03 vs -0.18 placebo mmol/L @ 8wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.6 mg/dL as posted
-0.83 vs -0.19 placebo mmol/L @ 12wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -15 mg/dL as posted
-0.72 vs -0.39 placebo mmol/L @ 16wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -13 mg/dL as posted
-0.75 vs -0.02 placebo mmol/L @ 20wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -13.6 mg/dL as posted
-0.47 vs 0.12 placebo mmol/L @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.4 mg/dL as posted
-0.94 vs -0.2 Voglibose mmol/L @ 12wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17 mg/dL as posted
-0.94 vs -0.36 Voglibose mmol/L @ 16wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17 mg/dL as posted
-0.77 vs -0.26 Voglibose mmol/L @ 20wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.8 mg/dL as posted
-0.77 vs -0.46 Voglibose mmol/L @ 24wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.8 mg/dL as posted
-0.78 vs -0.4 Voglibose mmol/L @ 28wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.1 mg/dL as posted
-0.83 vs -0.51 Voglibose mmol/L @ 32wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.9 mg/dL as posted
-0.94 vs -0.47 Voglibose mmol/L @ 36wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -16.9 mg/dL as posted
-0.87 vs -0.77 Voglibose mmol/L @ 40wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.7 mg/dL as posted
-1.05 vs -0.83 Voglibose mmol/L @ 44wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -19 mg/dL as posted
-1.27 vs -0.75 Voglibose mmol/L @ 48wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -22.8 mg/dL as posted
-1.19 vs -0.69 Voglibose mmol/L @ 52wk*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -21.4 mg/dL as posted
-0.95 vs -0.49 Voglibose mmol/L*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17.1 mg/dL as posted
-0.79 vs 0.1 placebo mmol/L @ 2wk*25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.3 mg/dL as posted
-1.05 vs 0.47 placebo mmol/L @ 4wk*25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -19 mg/dL as posted
-1.03 vs 0.32 placebo mmol/L @ 8wk*25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -18.6 mg/dL as posted
-0.97 vs 0.31 placebo mmol/L @ 12wk*25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17.5 mg/dL as posted
-1.36 vs 0.27 placebo mmol/L @ 6.14wk*25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -24.5 mg/dL as posted
-1.5 vs 0.47 placebo mmol/L @ 12.14wk*25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -27 mg/dL as posted
-0.28 vs 0.35 placebo mmol/L @ 1wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5 mg/dL as posted
-0.17 vs 0.06 placebo mmol/L @ 2wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -3.1 mg/dL as posted
-0.28 vs 0.29 placebo mmol/L @ 4wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5 mg/dL as posted
-0.75 vs 0.3 placebo mmol/L @ 8wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -13.5 mg/dL as posted
-0.29 vs -0.08 placebo mmol/L @ 12wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5.2 mg/dL as posted
-0.29 vs 0.26 placebo mmol/L @ 16wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5.3 mg/dL as posted
-0.23 vs 0.48 placebo mmol/L @ 20wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.2 mg/dL as posted
0.13 vs 0.32 placebo mmol/L @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from 2.3 mg/dL as posted
-0.48 vs 0.26 placebo mmol/L @ 1wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -8.6 mg/dL as posted
-0.81 vs 0.21 placebo mmol/L @ 2wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.6 mg/dL as posted
-0.87 vs 0.16 placebo mmol/L @ 4wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -15.6 mg/dL as posted
-0.79 vs 0.14 placebo mmol/L @ 8wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.3 mg/dL as posted
-0.85 vs 0.07 placebo mmol/L @ 12wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -15.3 mg/dL as posted
-0.81 vs 0.29 placebo mmol/L @ 16wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.6 mg/dL as posted
-0.68 vs 0.39 placebo mmol/L @ 20wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.3 mg/dL as posted
-0.57 vs 0.63 placebo mmol/L @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.3 mg/dL as posted
-0.66 vs 0.32 placebo mmol/L @ 1wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.9 mg/dL as posted
-0.64 vs 0.26 placebo mmol/L @ 2wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.6 mg/dL as posted
-0.92 vs 0.4 placebo mmol/L @ 4wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.6 mg/dL as posted
-0.67 vs 0.39 placebo mmol/L @ 8wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12.1 mg/dL as posted
-0.82 vs 0.64 placebo mmol/L @ 12wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.7 mg/dL as posted
-0.82 vs 0.56 placebo mmol/L @ 16wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.7 mg/dL as posted
-0.68 vs 0.48 placebo mmol/L @ 20wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12.3 mg/dL as posted
-0.54 vs 0.69 placebo mmol/L @ 26wk*12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -9.7 mg/dL as posted
-0.8 vs 0.1 placebo mmol/L @ 1wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.5 mg/dL as posted
-1.22 vs 0.27 placebo mmol/L @ 2wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.9 mg/dL as posted
-1.13 vs 0.21 placebo mmol/L @ 4wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.4 mg/dL as posted
-1.08 vs 0.32 placebo mmol/L @ 8wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.5 mg/dL as posted
-1.07 vs 0.19 placebo mmol/L @ 12wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.3 mg/dL as posted
-0.9 vs 0.08 placebo mmol/L @ 16wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.2 mg/dL as posted
-0.48 vs 0.37 placebo mmol/L @ 20wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.7 mg/dL as posted
-0.73 vs 0.36 placebo mmol/L @ 26wk*12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -13.2 mg/dL as posted
-0.79 vs -0.15 placebo mmol/L @ 1wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.2 mg/dL as posted
-1.17 vs -0.1 placebo mmol/L @ 2wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21 mg/dL as posted
-1.32 vs -0.17 placebo mmol/L @ 4wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -23.7 mg/dL as posted
-1.25 vs -0.34 placebo mmol/L @ 8wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.6 mg/dL as posted
-1.13 vs -0.55 placebo mmol/L @ 12wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.4 mg/dL as posted
-1.02 vs -0.46 placebo mmol/L @ 16wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.3 mg/dL as posted
-1.22 vs -0.36 placebo mmol/L @ 20wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.9 mg/dL as posted
-1.09 vs -0.32 placebo mmol/L @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.7 mg/dL as posted
-0.79 vs -0.03 placebo mmol/L @ 1wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.3 mg/dL as posted
-0.97 vs -0.04 placebo mmol/L @ 2wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.4 mg/dL as posted
-1.02 vs -0.03 placebo mmol/L @ 4wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.4 mg/dL as posted
-1.09 vs 0.02 placebo mmol/L @ 8wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.6 mg/dL as posted
-0.94 vs 0.02 placebo mmol/L @ 12wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.9 mg/dL as posted
-0.99 vs 0.07 placebo mmol/L @ 16wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.8 mg/dL as posted
-1 vs -0.01 placebo mmol/L @ 20wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.1 mg/dL as posted
-1.04 vs 0 placebo mmol/L @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.7 mg/dL as posted
-0.65 vs 0.02 placebo mmol/L @ 1wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.8 mg/dL as posted
-0.93 vs -0.1 placebo mmol/L @ 2wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.7 mg/dL as posted
-0.81 vs -0.21 placebo mmol/L @ 4wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.6 mg/dL as posted
-1.1 vs -0.18 placebo mmol/L @ 8wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.9 mg/dL as posted
-0.75 vs -0.19 placebo mmol/L @ 12wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -13.5 mg/dL as posted
-0.5 vs -0.39 placebo mmol/L @ 16wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -9 mg/dL as posted
-0.52 vs -0.02 placebo mmol/L @ 20wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -9.3 mg/dL as posted
-0.26 vs 0.12 placebo mmol/L @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -4.7 mg/dL as posted
-0.86 vs -0.19 Voglibose mmol/L @ 2wk*12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -15.5 mg/dL as posted
-0.9 vs -0.03 Voglibose mmol/L @ 4wk*12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -16.2 mg/dL as posted
-1.15 vs -0.14 Voglibose mmol/L @ 8wk*12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -20.8 mg/dL as posted
-1.06 vs -0.31 Voglibose mmol/L @ 12wk*12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -19.1 mg/dL as posted
-0.85 vs -0.2 Voglibose mmol/L @ 12wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.3 mg/dL as posted
-0.88 vs -0.36 Voglibose mmol/L @ 16wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.8 mg/dL as posted
-0.85 vs -0.26 Voglibose mmol/L @ 20wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.3 mg/dL as posted
-0.65 vs -0.46 Voglibose mmol/L @ 24wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -11.7 mg/dL as posted
-0.74 vs -0.4 Voglibose mmol/L @ 28wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.4 mg/dL as posted
-0.72 vs -0.51 Voglibose mmol/L @ 32wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -12.9 mg/dL as posted
-0.79 vs -0.47 Voglibose mmol/L @ 36wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.3 mg/dL as posted
-0.82 vs -0.77 Voglibose mmol/L @ 40wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.8 mg/dL as posted
-1.04 vs -0.83 Voglibose mmol/L @ 44wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -18.7 mg/dL as posted
-1.15 vs -0.75 Voglibose mmol/L @ 48wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.8 mg/dL as posted
-1.08 vs -0.69 Voglibose mmol/L @ 52wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -19.5 mg/dL as posted
-0.86 vs -0.49 Voglibose mmol/L*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.5 mg/dL as posted
-0.88 vs 0.1 placebo mmol/L @ 2wk*12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15.9 mg/dL as posted
-1.16 vs 0.47 placebo mmol/L @ 4wk*12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.9 mg/dL as posted
-1.03 vs 0.32 placebo mmol/L @ 8wk*12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -18.5 mg/dL as posted
-0.81 vs 0.31 placebo mmol/L @ 12wk*12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.6 mg/dL as posted
-0.64 vs 0.27 placebo mmol/L @ 6.14wk*12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -11.5 mg/dL as posted
-0.28 vs 0.47 placebo mmol/L @ 12.14wk*12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -5.1 mg/dL as posted
-1.42 vs 0.27 placebo mmol/L @ 6.14wk*100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -25.6 mg/dL as posted
-1.16 vs 0.47 placebo mmol/L @ 12.14wk*100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.9 mg/dL as posted
-1.28 vs -0.2 Voglibose mmol/L @ 12wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -23 mg/dL as posted
-1.04 vs -0.36 Voglibose mmol/L @ 16wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -18.8 mg/dL as posted
-1.12 vs -0.26 Voglibose mmol/L @ 20wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.1 mg/dL as posted
-1.12 vs -0.46 Voglibose mmol/L @ 24wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.2 mg/dL as posted
-1.1 vs -0.4 Voglibose mmol/L @ 28wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -19.9 mg/dL as posted
-1.13 vs -0.51 Voglibose mmol/L @ 32wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.3 mg/dL as posted
-1.16 vs -0.47 Voglibose mmol/L @ 36wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -20.9 mg/dL as posted
-1.29 vs -0.77 Voglibose mmol/L @ 40wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -23.2 mg/dL as posted
-1.37 vs -0.83 Voglibose mmol/L @ 44wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -24.7 mg/dL as posted
-1.41 vs -0.75 Voglibose mmol/L @ 48wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -25.4 mg/dL as posted
-1.44 vs -0.69 Voglibose mmol/L @ 52wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -26 mg/dL as posted
-1.53 vs -0.49 Voglibose mmol/L*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -27.6 mg/dL as posted
-1.2 vs 0.1 placebo mmol/L @ 2wk*50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -21.7 mg/dL as posted
-1.29 vs 0.47 placebo mmol/L @ 4wk*50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -23.3 mg/dL as posted
-1.25 vs 0.32 placebo mmol/L @ 8wk*50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -22.6 mg/dL as posted
-1.25 vs 0.31 placebo mmol/L @ 12wk*50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -22.6 mg/dL as posted
-0.99 vs 0.27 placebo mmol/L @ 6.14wk*50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17.9 mg/dL as posted
-0.89 vs 0.47 placebo mmol/L @ 12.14wk*50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -16.1 mg/dL as posted
-0.63 vs -0.43 Glipizide mmol/L @ 2wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.4 mg/dL as posted
-0.64 vs -0.57 Glipizide mmol/L @ 4wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.6 mg/dL as posted
-0.64 vs -0.52 Glipizide mmol/L @ 8wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.6 mg/dL as posted
-0.62 vs -0.52 Glipizide mmol/L @ 12wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.2 mg/dL as posted
-0.55 vs -0.39 Glipizide mmol/L @ 16wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.9 mg/dL as posted
-0.56 vs -0.31 Glipizide mmol/L @ 20wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.1 mg/dL as posted
-0.56 vs -0.24 Glipizide mmol/L @ 26wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.1 mg/dL as posted
-0.47 vs -0.03 Glipizide mmol/L @ 39wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -8.4 mg/dL as posted
-0.39 vs 0.05 Glipizide mmol/L @ 52wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -7 mg/dL as posted
-0.33 vs 0.08 Glipizide mmol/L @ 65wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -5.9 mg/dL as posted
-0.28 vs 0.28 Glipizide mmol/L @ 78wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -5.1 mg/dL as posted
-0.19 vs 0.27 Glipizide mmol/L @ 91wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -3.4 mg/dL as posted
-0.18 vs 0.3 Glipizide mmol/L @ 104wk*25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -3.2 mg/dL as posted
-2.16 vs -0.23 placebo mmol/L @ 4wk*25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -38.826 mg/dL as posted
-2.12 vs 0.27 placebo mmol/L @ 8wk*25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -38.242 mg/dL as posted
-2.14 vs 0.66 placebo mmol/L @ 16wk*25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -38.481 mg/dL as posted
-0.86 vs -0.03 Pioglitazone 45 mg + Metformin mmol/L @ 2wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -15.5 mg/dL as posted
-0.98 vs -0.08 Pioglitazone 45 mg + Metformin mmol/L @ 4wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.7 mg/dL as posted
-1.06 vs -0.32 Pioglitazone 45 mg + Metformin mmol/L @ 8wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.1 mg/dL as posted
-1.09 vs -0.27 Pioglitazone 45 mg + Metformin mmol/L @ 12wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.6 mg/dL as posted
-1 vs -0.25 Pioglitazone 45 mg + Metformin mmol/L @ 16wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -18 mg/dL as posted
-0.91 vs -0.32 Pioglitazone 45 mg + Metformin mmol/L @ 20wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -16.4 mg/dL as posted
-0.95 vs -0.27 Pioglitazone 45 mg + Metformin mmol/L @ 26wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.1 mg/dL as posted
-0.75 vs -0.34 Pioglitazone 45 mg + Metformin mmol/L @ 34wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.6 mg/dL as posted
-0.88 vs -0.27 Pioglitazone 45 mg + Metformin mmol/L @ 42wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -15.9 mg/dL as posted
-0.81 vs -0.21 Pioglitazone 45 mg + Metformin mmol/L @ 52wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -14.6 mg/dL as posted
-1.16 vs 0.1 placebo mmol/L @ 1wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -20.9 mg/dL as posted
-1.29 vs 0.1 placebo mmol/L @ 1wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -23.2 mg/dL as posted
-1.39 vs 0.1 placebo mmol/L @ 1wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -25 mg/dL as posted
-1.76 vs 0.27 placebo mmol/L @ 2wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.7 mg/dL as posted
-1.74 vs 0.27 placebo mmol/L @ 2wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.3 mg/dL as posted
-1.76 vs 0.27 placebo mmol/L @ 2wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.7 mg/dL as posted
-2.07 vs 0.21 placebo mmol/L @ 4wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.3 mg/dL as posted
-2 vs 0.21 placebo mmol/L @ 4wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -36 mg/dL as posted
-2.56 vs 0.21 placebo mmol/L @ 4wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -46.2 mg/dL as posted
-2.18 vs 0.32 placebo mmol/L @ 8wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -39.3 mg/dL as posted
-2.45 vs 0.32 placebo mmol/L @ 8wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -44.1 mg/dL as posted
-2.9 vs 0.32 placebo mmol/L @ 8wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -52.3 mg/dL as posted
-2.36 vs 0.19 placebo mmol/L @ 12wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -42.5 mg/dL as posted
-2.72 vs 0.19 placebo mmol/L @ 12wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -49 mg/dL as posted
-2.85 vs 0.19 placebo mmol/L @ 12wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -51.4 mg/dL as posted
-2.17 vs 0.08 placebo mmol/L @ 16wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -39.1 mg/dL as posted
-2.41 vs 0.08 placebo mmol/L @ 16wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -43.4 mg/dL as posted
-2.99 vs 0.08 placebo mmol/L @ 16wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -53.8 mg/dL as posted
-2.18 vs 0.37 placebo mmol/L @ 20wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -39.3 mg/dL as posted
-2.39 vs 0.37 placebo mmol/L @ 20wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -43.1 mg/dL as posted
-2.91 vs 0.37 placebo mmol/L @ 20wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -52.4 mg/dL as posted
-2.11 vs 0.36 placebo mmol/L @ 26wk*25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -38 mg/dL as posted
-2.31 vs 0.36 placebo mmol/L @ 26wk*25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -41.7 mg/dL as posted
-2.93 vs 0.36 placebo mmol/L @ 26wk*25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -52.7 mg/dL as posted
-1.48 vs -0.41 Pioglitazone 30 mg mmol/L @ 1wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -26.6 mg/dL as posted
-1.86 vs -0.79 Pioglitazone 30 mg mmol/L @ 2wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.5 mg/dL as posted
-2.3 vs -1.77 Pioglitazone 30 mg mmol/L @ 4wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -41.4 mg/dL as posted
-2.8 vs -2.11 Pioglitazone 30 mg mmol/L @ 8wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -50.4 mg/dL as posted
-2.88 vs -2.35 Pioglitazone 30 mg mmol/L @ 12wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -51.9 mg/dL as posted
-2.93 vs -2.25 Pioglitazone 30 mg mmol/L @ 16wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -52.7 mg/dL as posted
-3 vs -2.33 Pioglitazone 30 mg mmol/L @ 20wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -54 mg/dL as posted
-2.79 vs -2.07 Pioglitazone 30 mg mmol/L @ 26wk*25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -50.2 mg/dL as posted
-0.97 vs 0.01 Glimepiride mmol/L @ 2wk*25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.4 mg/dL as posted
-1.27 vs 0.11 Glimepiride mmol/L @ 4wk*25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.9 mg/dL as posted
-0.97 vs 0.29 Glimepiride mmol/L @ 8wk*25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.4 mg/dL as posted
-0.88 vs 0.33 Glimepiride mmol/L @ 12wk*25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.9 mg/dL as posted
-0.94 vs -0.22 Pioglitazone mmol/L @ 2wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17 mg/dL as posted
-0.99 vs -0.17 Pioglitazone mmol/L @ 4wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.9 mg/dL as posted
-1.18 vs -0.23 Pioglitazone mmol/L @ 8wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.3 mg/dL as posted
-1.05 vs -0.13 Pioglitazone mmol/L @ 12wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.9 mg/dL as posted
-1.04 vs -0.19 Voglibose mmol/L @ 2wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.8 mg/dL as posted
-1.25 vs -0.03 Voglibose mmol/L @ 4wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.6 mg/dL as posted
-1.22 vs -0.14 Voglibose mmol/L @ 8wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.9 mg/dL as posted
-1.03 vs -0.31 Voglibose mmol/L @ 12wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.5 mg/dL as posted
-0.57 vs -0.43 Glipizide mmol/L @ 2wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.2 mg/dL as posted
-0.59 vs -0.57 Glipizide mmol/L @ 4wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.6 mg/dL as posted
-0.51 vs -0.52 Glipizide mmol/L @ 8wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.2 mg/dL as posted
-0.59 vs -0.52 Glipizide mmol/L @ 12wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.7 mg/dL as posted
-0.48 vs -0.39 Glipizide mmol/L @ 16wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -8.6 mg/dL as posted
-0.42 vs -0.31 Glipizide mmol/L @ 20wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -7.6 mg/dL as posted
-0.42 vs -0.24 Glipizide mmol/L @ 26wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -7.5 mg/dL as posted
-0.38 vs -0.03 Glipizide mmol/L @ 39wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -6.9 mg/dL as posted
-0.28 vs 0.05 Glipizide mmol/L @ 52wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -5 mg/dL as posted
-0.19 vs 0.08 Glipizide mmol/L @ 65wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -3.4 mg/dL as posted
-0.16 vs 0.28 Glipizide mmol/L @ 78wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -2.8 mg/dL as posted
-0.05 vs 0.27 Glipizide mmol/L @ 91wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -0.9 mg/dL as posted
-0.05 vs 0.3 Glipizide mmol/L @ 104wk*12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -0.9 mg/dL as posted
-1.82 vs 0.32 placebo mmol/L @ 1wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -32.7 mg/dL as posted
-2.01 vs 0.32 placebo mmol/L @ 1wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -36.3 mg/dL as posted
-1.91 vs 0.26 placebo mmol/L @ 2wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -34.5 mg/dL as posted
-2.42 vs 0.26 placebo mmol/L @ 2wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -43.6 mg/dL as posted
-2.09 vs 0.4 placebo mmol/L @ 4wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.6 mg/dL as posted
-2.45 vs 0.4 placebo mmol/L @ 4wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -44.1 mg/dL as posted
-1.83 vs 0.39 placebo mmol/L @ 8wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -32.9 mg/dL as posted
-2.43 vs 0.39 placebo mmol/L @ 8wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -43.8 mg/dL as posted
-1.75 vs 0.64 placebo mmol/L @ 12wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.6 mg/dL as posted
-2.48 vs 0.64 placebo mmol/L @ 12wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -44.7 mg/dL as posted
-1.99 vs 0.56 placebo mmol/L @ 16wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.9 mg/dL as posted
-2.65 vs 0.56 placebo mmol/L @ 16wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -47.7 mg/dL as posted
-1.88 vs 0.48 placebo mmol/L @ 20wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.8 mg/dL as posted
-2.48 vs 0.48 placebo mmol/L @ 20wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -44.6 mg/dL as posted
-1.76 vs 0.69 placebo mmol/L @ 26wk*alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.7 mg/dL as posted
-2.55 vs 0.69 placebo mmol/L @ 26wk*alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -45.9 mg/dL as posted
-1.18 vs 0.1 placebo mmol/L @ 1wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -21.3 mg/dL as posted
-1.29 vs 0.1 placebo mmol/L @ 1wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -23.2 mg/dL as posted
-1.29 vs 0.1 placebo mmol/L @ 1wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -23.2 mg/dL as posted
-1.67 vs 0.27 placebo mmol/L @ 2wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.1 mg/dL as posted
-1.67 vs 0.27 placebo mmol/L @ 2wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30 mg/dL as posted
-1.71 vs 0.27 placebo mmol/L @ 2wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.8 mg/dL as posted
-1.96 vs 0.21 placebo mmol/L @ 4wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted
-2.08 vs 0.21 placebo mmol/L @ 4wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.4 mg/dL as posted
-2.1 vs 0.21 placebo mmol/L @ 4wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.8 mg/dL as posted
-2.35 vs 0.32 placebo mmol/L @ 8wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -42.3 mg/dL as posted
-2.25 vs 0.32 placebo mmol/L @ 8wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -40.5 mg/dL as posted
-2.44 vs 0.32 placebo mmol/L @ 8wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -44 mg/dL as posted
-2.38 vs 0.19 placebo mmol/L @ 12wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -42.9 mg/dL as posted
-2.38 vs 0.19 placebo mmol/L @ 12wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -42.8 mg/dL as posted
-2.73 vs 0.19 placebo mmol/L @ 12wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -49.2 mg/dL as posted
-2.31 vs 0.08 placebo mmol/L @ 16wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -41.6 mg/dL as posted
-2.3 vs 0.08 placebo mmol/L @ 16wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -41.5 mg/dL as posted
-2.66 vs 0.08 placebo mmol/L @ 16wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -47.9 mg/dL as posted
-2.39 vs 0.37 placebo mmol/L @ 20wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -43 mg/dL as posted
-2.28 vs 0.37 placebo mmol/L @ 20wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -41.1 mg/dL as posted
-2.6 vs 0.37 placebo mmol/L @ 20wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -46.8 mg/dL as posted
-2.33 vs 0.36 placebo mmol/L @ 26wk*12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -42 mg/dL as posted
-2.34 vs 0.36 placebo mmol/L @ 26wk*12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -42.2 mg/dL as posted
-2.85 vs 0.36 placebo mmol/L @ 26wk*12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -51.3 mg/dL as posted
-1.29 vs -0.41 Pioglitazone 30 mg mmol/L @ 1wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted
-1.72 vs -0.79 Pioglitazone 30 mg mmol/L @ 2wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.9 mg/dL as posted
-2.2 vs -1.77 Pioglitazone 30 mg mmol/L @ 4wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -39.7 mg/dL as posted
-2.69 vs -2.11 Pioglitazone 30 mg mmol/L @ 8wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -48.4 mg/dL as posted
-2.74 vs -2.35 Pioglitazone 30 mg mmol/L @ 12wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -49.3 mg/dL as posted
-2.59 vs -2.25 Pioglitazone 30 mg mmol/L @ 16wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -46.6 mg/dL as posted
-2.64 vs -2.33 Pioglitazone 30 mg mmol/L @ 20wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -47.5 mg/dL as posted
-2.69 vs -2.07 Pioglitazone 30 mg mmol/L @ 26wk*12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -48.5 mg/dL as posted
-0.97 vs 0.01 Glimepiride mmol/L @ 2wk*12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted
-1.18 vs 0.11 Glimepiride mmol/L @ 4wk*12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.2 mg/dL as posted
-1.24 vs 0.29 Glimepiride mmol/L @ 8wk*12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.3 mg/dL as posted
-1.24 vs 0.33 Glimepiride mmol/L @ 12wk*12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.3 mg/dL as posted
-0.71 vs -0.22 Pioglitazone mmol/L @ 2wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -12.8 mg/dL as posted
-0.8 vs -0.17 Pioglitazone mmol/L @ 4wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -14.4 mg/dL as posted
-0.95 vs -0.23 Pioglitazone mmol/L @ 8wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.1 mg/dL as posted
-0.83 vs -0.13 Pioglitazone mmol/L @ 12wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -14.9 mg/dL as posted
-0.67 vs -0.2 Voglibose mmol/L @ 12wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -12.1 mg/dL as posted
-0.6 vs -0.36 Voglibose mmol/L @ 16wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -10.8 mg/dL as posted
-0.64 vs -0.26 Voglibose mmol/L @ 20wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -11.5 mg/dL as posted
-0.59 vs -0.46 Voglibose mmol/L @ 24wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -10.6 mg/dL as posted
-0.53 vs -0.4 Voglibose mmol/L @ 28wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -9.6 mg/dL as posted
-0.8 vs -0.51 Voglibose mmol/L @ 32wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.5 mg/dL as posted
-0.59 vs -0.47 Voglibose mmol/L @ 36wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -10.7 mg/dL as posted
-0.75 vs -0.77 Voglibose mmol/L @ 40wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.5 mg/dL as posted
-0.93 vs -0.83 Voglibose mmol/L @ 44wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -16.7 mg/dL as posted
-0.89 vs -0.75 Voglibose mmol/L @ 48wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -16 mg/dL as posted
-0.76 vs -0.69 Voglibose mmol/L @ 52wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.7 mg/dL as posted
-0.58 vs -0.49 Voglibose mmol/L*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -10.4 mg/dL as posted
-0.77 vs 0.1 placebo mmol/L @ 2wk*6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.8 mg/dL as posted
-0.89 vs 0.47 placebo mmol/L @ 4wk*6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -16 mg/dL as posted
-0.67 vs 0.32 placebo mmol/L @ 8wk*6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -12 mg/dL as posted
-0.52 vs 0.31 placebo mmol/L @ 12wk*6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -9.3 mg/dL as posted
-0.41 vs 0.27 placebo mmol/L @ 6.14wk*6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -7.3 mg/dL as posted
-0.43 vs 0.47 placebo mmol/L @ 12.14wk*6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -7.8 mg/dL as posted
-0.719 vs -0.331 placebo mmol/L @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.985 vs -0.331 placebo mmol/L @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.985 vs -0.331 placebo mmol/L @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.015 vs -0.33 placebo mmol/L @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-1.265 vs -0.33 placebo mmol/L @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.924 vs -0.33 placebo mmol/L @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.123 vs -0.411 placebo mmol/L @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-1.27 vs -0.411 placebo mmol/L @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.177 vs -0.411 placebo mmol/L @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.243 vs -0.317 placebo mmol/L @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-1.24 vs -0.317 placebo mmol/L @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.07 vs -0.317 placebo mmol/L @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
Rescue 19.5% (n=128) vs 40.3% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 25 participants as posted
show 5 more results
9% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 18 participants as posted
15.7% (n=198) vs 28.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 31 participants as posted
20.6% (n=131) vs 40.3% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
9.7% (n=196) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
14.9% (n=201) vs 28.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 30 participants as posted
HbA1c 6.5 or Less 2.3% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
show 7 more results
20.6% (n=131) vs 10.9% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
20.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
14.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 28 participants as posted
2.3% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
17.3% (n=133) vs 10.9% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
17.3% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 34 participants as posted
9.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
HbA1c 7.0 or Less 7.8% (n=129) vs 0.8% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 10 participants as posted
show 7 more results
44.3% (n=131) vs 23.4% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 58 participants as posted
49.2% (n=199) vs 34% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 98 participants as posted
34.8% (n=198) vs 18.2% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 69 participants as posted
8.4% (n=131) vs 0.8% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
47.4% (n=133) vs 23.4% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 63 participants as posted
44.2% (n=197) vs 34% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
29.6% (n=203) vs 18.2% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 60 participants as posted
HbA1c 7 5 or Less 25.6% (n=129) vs 3.9% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 33 participants as posted
show 7 more results
67.2% (n=131) vs 39.1% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 participants as posted
70.9% (n=199) vs 48.5% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 141 participants as posted
56.6% (n=198) vs 33.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 112 participants as posted
16.8% (n=131) vs 3.9% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
60.9% (n=133) vs 39.1% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 81 participants as posted
64.5% (n=197) vs 48.5% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 127 participants as posted
46.3% (n=203) vs 33.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 94 participants as posted
HbA1c Decrease 0.5 54.3% (n=129) vs 31% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
show 9 more results
55% (n=131) vs 29.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 72 participants as posted
64.3% (n=199) vs 26.8% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 128 participants as posted
58.9% (n=207) vs 26.9% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 122 participants as posted
50.5% (n=198) vs 26.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 100 participants as posted
53.4% (n=131) vs 31% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
50.4% (n=133) vs 29.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 67 participants as posted
59.9% (n=197) vs 26.8% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 118 participants as posted
57.7% (n=213) vs 26.9% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 123 participants as posted
47.3% (n=203) vs 26.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 96 participants as posted
HbA1c Decrease 1 0 36.4% (n=129) vs 13.2% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 47 participants as posted
show 9 more results
29.8% (n=131) vs 10.9% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 39 participants as posted
36.7% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 73 participants as posted
30% (n=207) vs 8.7% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 62 participants as posted
29.8% (n=198) vs 13.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 59 participants as posted
31.3% (n=131) vs 13.2% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 41 participants as posted
28.6% (n=133) vs 10.9% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 38 participants as posted
32.5% (n=197) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 64 participants as posted
28.6% (n=213) vs 8.7% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 61 participants as posted
18.7% (n=203) vs 13.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 38 participants as posted
HbA1c Decrease 1 5 17.8% (n=129) vs 4.7% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
show 9 more results
12.2% (n=131) vs 4.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 16 participants as posted
18.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 37 participants as posted
11.6% (n=207) vs 5.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
12.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
16.8% (n=131) vs 4.7% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
8.3% (n=133) vs 4.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
16.2% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 32 participants as posted
9.4% (n=213) vs 5.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 20 participants as posted
6.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 13 participants as posted
HbA1c Decrease 2 0 8.5% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
show 9 more results
4.6% (n=131) vs 1.6% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 6 participants as posted
7% (n=199) vs 3.1% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 14 participants as posted
2.4% (n=207) vs 3.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
6.1% (n=198) vs 4% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
8.4% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
2.3% (n=133) vs 1.6% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
6.1% (n=197) vs 3.1% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
3.3% (n=213) vs 3.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 7 participants as posted
2.5% (n=203) vs 4% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
Weight 0.18 vs 0.39 placebo kg @ 8wk25 mg QD
absolute change · kg
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 111 more results
0.31 vs 0.5 placebo kg @ 12wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.45 vs 0.73 placebo kg @ 20wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6 vs 0.63 placebo kg @ 26wk25 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.03 vs -0.36 placebo kg @ 8wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.05 vs -0.25 placebo kg @ 12wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.17 vs -0.17 placebo kg @ 20wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.22 vs 0.18 placebo kg @ 26wk25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.45 vs -0.13 placebo kg @ 8wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.56 vs -0.46 placebo kg @ 12wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.48 vs -0.55 placebo kg @ 20wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.67 vs -0.66 placebo kg @ 26wk25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.34 vs 0.58 Pioglitazone 30 mg kg @ 8wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.78 vs 0.96 Pioglitazone 30 mg kg @ 12wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.47 vs 1.56 Pioglitazone 30 mg kg @ 20wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
-0.29 vs 2.19 Pioglitazone 30 mg kg @ 26wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
0.39 vs 0.36 placebo kg @ 8wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.64 vs 0.6 placebo kg @ 12wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.93 vs 0.94 placebo kg @ 20wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
1.09 vs 1.04 placebo kg @ 26wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.53 vs -0.12 placebo kg @ 8wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.64 vs -0.57 placebo kg @ 12wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.58 vs -0.4 placebo kg @ 20wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.67 vs -0.39 placebo kg @ 26wk25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
0.33 vs -0.27 placebo kg @ 8wk25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.4 vs -0.12 placebo kg @ 12wk25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.61 vs -0.3 placebo kg @ 20wk25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.68 vs -0.2 placebo kg @ 26wk25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.1 vs 0.39 placebo kg @ 8wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.44 vs 0.5 placebo kg @ 12wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.55 vs 0.73 placebo kg @ 20wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.68 vs 0.63 placebo kg @ 26wk12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.01 vs -0.36 placebo kg @ 8wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.37 vs -0.25 placebo kg @ 12wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.18 vs -0.17 placebo kg @ 20wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.09 vs 0.18 placebo kg @ 26wk12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.05 vs -0.13 placebo kg @ 8wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.14 vs -0.46 placebo kg @ 12wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.08 vs -0.55 placebo kg @ 20wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
-0.02 vs -0.66 placebo kg @ 26wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.46 vs 0.36 placebo kg @ 8wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.74 vs 0.6 placebo kg @ 12wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
1.14 vs 0.94 placebo kg @ 20wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
1.46 vs 1.04 placebo kg @ 26wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.12 placebo kg @ 8wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.28 vs -0.57 placebo kg @ 12wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.38 vs -0.4 placebo kg @ 20wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
-0.39 vs -0.39 placebo kg @ 26wk12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
0.47 vs -0.27 placebo kg @ 8wk12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.58 vs -0.12 placebo kg @ 12wk12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.79 vs -0.3 placebo kg @ 20wk12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
0.6 vs -0.2 placebo kg @ 26wk12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
-0.53 vs 0.71 Glipizide kg @ 12wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.71 vs 0.86 Glipizide kg @ 26wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.86 vs 0.97 Glipizide kg @ 39wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.9 vs 0.89 Glipizide kg @ 52wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.92 vs 0.87 Glipizide kg @ 65wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.94 vs 0.88 Glipizide kg @ 78wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.88 vs 0.89 Glipizide kg @ 91wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.89 vs 0.95 Glipizide kg @ 104wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
0.18 vs 0.32 Pioglitazone 45 mg + Metformin kg @ 4wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.31 vs 0.51 Pioglitazone 45 mg + Metformin kg @ 8wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.35 vs 0.64 Pioglitazone 45 mg + Metformin kg @ 12wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.73 vs 0.97 Pioglitazone 45 mg + Metformin kg @ 26wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.09 vs 1.52 Pioglitazone 45 mg + Metformin kg @ 42wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.1 vs 1.6 Pioglitazone 45 mg + Metformin kg @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.22 vs -0.13 placebo kg @ 8wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.74 vs -0.13 placebo kg @ 8wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.93 vs -0.13 placebo kg @ 8wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.39 vs -0.46 placebo kg @ 12wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.98 vs -0.46 placebo kg @ 12wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.08 vs -0.46 placebo kg @ 12wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.85 vs -0.55 placebo kg @ 20wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.76 vs -0.55 placebo kg @ 20wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.76 vs -0.55 placebo kg @ 20wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.27 vs -0.66 placebo kg @ 26wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.1 vs -0.66 placebo kg @ 26wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.25 vs -0.66 placebo kg @ 26wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.82 vs 0.58 Pioglitazone 30 mg kg @ 8wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
1.35 vs 0.96 Pioglitazone 30 mg kg @ 12wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
2.36 vs 1.56 Pioglitazone 30 mg kg @ 20wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3.14 vs 2.19 Pioglitazone 30 mg kg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-0.51 vs 0.71 Glipizide kg @ 12wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.65 vs 0.86 Glipizide kg @ 26wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.6 vs 0.97 Glipizide kg @ 39wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.63 vs 0.89 Glipizide kg @ 52wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.7 vs 0.87 Glipizide kg @ 65wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.78 vs 0.88 Glipizide kg @ 78wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.67 vs 0.89 Glipizide kg @ 91wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
-0.68 vs 0.95 Glipizide kg @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
0.09 vs -0.13 placebo kg @ 8wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.49 vs -0.13 placebo kg @ 8wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.43 vs -0.13 placebo kg @ 8wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.22 vs -0.46 placebo kg @ 12wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.6 vs -0.46 placebo kg @ 12wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.88 vs -0.46 placebo kg @ 12wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.96 vs -0.55 placebo kg @ 20wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.45 vs -0.55 placebo kg @ 20wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.93 vs -0.55 placebo kg @ 20wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.25 vs -0.66 placebo kg @ 26wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.89 vs -0.66 placebo kg @ 26wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.3 vs -0.66 placebo kg @ 26wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.7 vs 0.58 Pioglitazone 30 mg kg @ 8wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
1.22 vs 0.96 Pioglitazone 30 mg kg @ 12wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
1.86 vs 1.56 Pioglitazone 30 mg kg @ 20wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
2.51 vs 2.19 Pioglitazone 30 mg kg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
-0.71 vs -1.04 placebo kg @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.43 vs -1.04 placebo kg @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.15 vs -1.04 placebo kg @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.89 vs -1.55 placebo kg @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
-0.76 vs -1.55 placebo kg @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.1 vs -1.55 placebo kg @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
MACE 3-point Composite 11.3% (n=2701) vs 11.8% (n=2679) placebo
event count · % of participants
NCT00968708 · Phase 3

+ 63 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Yogliptin's landscape